Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial (original) (raw)

Journal Article

,

1

Departments of Internal Medicine, National Taiwan University Hospital

,

Taipei

Search for other works by this author on:

,

1

Departments of Internal Medicine, National Taiwan University Hospital

,

Taipei

Search for other works by this author on:

,

4

Department of Internal Medicine, Taipei Municipal Hospital

,

Ren-Ai Branch, Taipei

Search for other works by this author on:

,

5

Department of Internal Medicine, Far Eastern Memorial Hospital

,

Taipei

Search for other works by this author on:

,

7

Departments of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch

,

Douliou

Search for other works by this author on:

,

9

Department of Internal Medicine, Taichung Veterans General Hospital

,

Taichung, Taiwan

Search for other works by this author on:

,

6

Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch

,

Taipei

Search for other works by this author on:

,

6

Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch

,

Taipei

Search for other works by this author on:

,

6

Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch

,

Taipei

Search for other works by this author on:

,

1

Departments of Internal Medicine, National Taiwan University Hospital

,

Taipei

2

Medical Research, National Taiwan University Hospital

,

Taipei

3

Hepatitis Research Center, National Taiwan University Hospital

,

Taipei

Search for other works by this author on:

... Show more

Published:

15 November 2008

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Chen-Hua Liu, Chun-Jen Liu, Chih-Lin Lin, Cheng-Chao Liang, Shih-Jer Hsu, Sheng-Shun Yang, Ching-Sheng Hsu, Tai-Chung Tseng, Chia-Chi Wang, Ming-Yang Lai, Jun-Herng Chen, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao1, Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial, Clinical Infectious Diseases, Volume 47, Issue 10, 15 November 2008, Pages 1260–1269, https://doi.org/10.1086/592579
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Background. Comparable sustained virologic response (SVR) rates have been documented between Asian patients who received 24 weeks of pegylated interferon (IFN) plus ribavirin and white patients who received 48 weeks of combination therapy for hepatitis C virus genotype 1 (HCV-1) infection. Whether a 48-week course of combination therapy shows a better SVR rate than a 24-week course of such therapy among Asian patients with HCV-1 infection has not been confirmed in multicenter, randomized studies.

Methods. In this multicenter, randomized trial, 308 treatment-naive HCV-1-infected Asian patients were randomly assigned to receive either 24 or 48 weeks of pegylated IFN-α-2a (180 µg per week) plus ribavirin (1000–1200 mg/day) therapy. The primary end point was SVR, defined as an undetectable serum HCV RNA level 24 weeks after discontinuation of therapy. In addition, rapid virologic response (RVR) was defined as an undetectable serum HCV RNA level at week 4 of therapy, and complete early virologic response was defined as an undetectable serum HCV RNA level at 12 weeks of therapy in the absence of RVR.

Results. By intention-to-treat analysis, patients who received 48 weeks of therapy had a significantly higher SVR rate than did those who received 24 weeks of therapy (76% vs. 56%; P<.001). Among patients with a baseline serum HCV RNA level <800,000 IU/mL and RVR, SVR rates were comparable between 24- and 48-week courses of therapy (94% vs. 100%; _P_=.13). In contrast, 48 weeks of therapy was associated with a significantly higher SVR rate than was 24 weeks of therapy among patients without RVR (39% vs.16%; _P_=.01) and among those who achieved a complete early virologic response (44% vs. 20%; _P_=.02).

Conclusions. In treatment-naive Asian patients with HCV-1 infection, 48 weeks of pegylated IFN-α-2a plus ribavirin therapy is associated with a higher SVR rate, compared with 24 weeks of such therapy. Patients with a baseline serum HCV RNA level <800,000 IU/mL and who have achieved an RVR can receive a 24-week course of therapy without compromising the SVR rates; however, those who have not achieved an RVR but who have achieved a complete early virologic response should receive a 48-week course of therapy.

Clinical trials registration. NCT00495131.

© 2008 by the Infectious Diseases Society of America

Topic:

• hepatitis c rna
• combined modality therapy
• interferons
• ribavirin
• infections
• human leukocyte interferon
• hepatitis c virus
• peginterferon
• ventricular rate rapid
• asian
• intention to treat
• therapy naive
• hepatitis c virus genotype 1
• sustained virologic response

You do not currently have access to this article.

I agree to the terms and conditions. You must accept the terms and conditions.

Submit a comment

Name

Affiliations

Comment title

Comment

You have entered an invalid code

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 2,790

2,380 Pageviews

410 PDF Downloads

Since 12/1/2016

Citations

170 Web of Science

×

Email alerts

More on this topic

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic